Why Incannex Is Rising In Pre-market?
(RTTNews) - Incannex Healthcare (IXHL) announced that the FDA has granted Fast Track designation for IHL-42X, the company's oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea. The Fast Track designation was supported by safety, efficacy, and pharmacokinetic results from the three clinical trials completed to date within the IHL-42X development program.
Incannex expects to receive detailed written feedback from the FDA in response to its Phase 2 data package and clinical development strategy. The company expects to provide further updates once it has received and reviewed this feedback.
Shares of Incannex are up 21% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.